Navigation Links
Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
Date:1/5/2016

RICHMOND, Calif., Jan. 5, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the Company's clinical and preclinical ZFP Therapeutic® programs and upcoming milestones, as well as an overview of Sangamo's business strategy at 9:30 am PT on Tuesday, January 12th, at the 34th Annual J.P. Morgan Healthcare Conference. The conference will be held from January 11-14 in San Francisco, CA.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations.  The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP™) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders.  In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

 

 

 


 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
3. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
5. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
6. Sangamo BioSciences Proposes Public Offering Of Common Stock
7. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
8. Sangamo BioSciences Reports Third Quarter 2013 Financial Results
9. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
10. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
11. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... 06, 2020 , ... VGXI, a highly regarded CDMO supporting ... purchase of greenfield for a new, expanded manufacturing facility. The site is located ... the initial acquisition, with an option to purchase an additional 21 acres for ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
Breaking Biology Technology:
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... Switzerland (PRWEB) , ... June ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that it ... company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and ...
Breaking Biology News(10 mins):